Wishing you a happy, hopeful, and productive new year from Clinical and Translational Science (CTS)!

2023 by the numbers:

• 3.9 Impact Factor (IF)
• 731,100 downloads (as of December 31, 2023)
• 227 articles e-published
• Published articles from 28 countries
• 33 days average duration from submission to first decision

Looking back at 2023, CTS has had a great year. One of our goals continues to be becoming a beacon for the field of translational science, fulfilling a major component of ASCPT’s Strategic Plan. Growth of CTS since we relaunched as part of the ASCPT Journal Family in 2016 is displayed in the graph above, which bodes well for continued successful future of the Journal.

Another achievement on the path to becoming a beacon for the field of translational science is the launch of a new, rapidly growing series of highly translational articles, mechanism of action (MOA) mini-reviews.  This new series of MOA mini-reviews provide a concise, readable understanding of new therapeutics.  Learn more by reading Associate Editor Mohamed Shahin’s excellent blog. Speaking of terrific new content, we have a special collection on Real-World Evidence/Real-World Data and a Call for Papers for a new special collection on Artificial Intelligence/Machine Learning (AI/ML) that is scheduled for initial, rolling publication in the second half of 2024.

In the spirit of a 2023 review, we wanted to celebrate our most impactful contributions. Looking forward to the next IF, the three most highly cited papers* in 2023 are listed below. Substantial and impactful COVID-19 research continued to be published in CTS in 2023; thus, unsurprisingly, two of the three most highly cited articles were related to COVID-19.

• COVID-19 vaccine hesitancy: Race/ethnicity, trust, and fear by Willis et al. (70 citations in 2023)
• SARS-CoV-2 infection as a trigger of autoimmune response by Sacchi et al. (27 citations in 2023)
• 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration by Wang et al. (26 citations in 2023)

IF is just one way to measure journal influence. Another important metric of impact is downloads, which also demonstrated strong results in 2023. Downloads are an obvious impact metric that measure how often journal readers take the time to download an article. CTS downloads have shown impressive growth since we relaunched as an ASCPT journal in 2016. Downloads also demonstrate the value of an Open Access journal, since there is no paywall to prospective readers. The 2023 download winners demonstrate a diversity of translational topics including COVID-19, nonclinical to clinical PK/PD translation, and systems‐based digital twins. Interestingly, the all-time most downloaded CTS article was a tutorial, Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial Applications by Chiodin et al. (50,889 downloads), which is consistent with our intended positive educational impact on the field of translational science. The three most downloaded 2023 CTS articles** were:

• Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials by Mitjà et al. (4,125 downloads)
• PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development by Oggianu et al. (3,628 downloads)
• Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL by Susilo et al. (2,884 downloads)

In our increasingly social media-connected world, another measure of journal influence is the Altmetric score, which is a measure of the global, public attention articles garner, including through news outlets and social media. Interestingly, the Altmetric score does not include LinkedIn posts, a major social media venue for ASCPT members. The three highest 2023 Altmetric scores*** in CTS were

• Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials by Mitjà et al.
• On the road to achieving work–life balance in academia by Martin and Stanfill.
• Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009–2018 by Wallace et al. 

Thanks to all the CTS authors and readers, ASCPT membership, and the many folks who make the Journal work – including editors, peer reviewers, as well as ASCPT and Wiley staff. CTS had another successful, impactful year on the journey to becoming a beacon of translational science. The Journal owes its success to each and every one of you. We, at CTS appreciate you!

Do you have the next IF, download, or Altmetric winner, new terrific MOA mini-review, or contribution for the AI/ML special collection? Submit to CTS, and find out. Are you curious about the top cited, downloaded, or Altmetric-winning papers? Read them today, and join us in 2024 to help drive our vision for translational science with your submissions.

_{*Preliminary 2023 impact factor “in-window” citations (i.e., those from articles that will count toward the next IF).} 

Sort by: Newest First Oldest First Most Popular Most unliked